Develops cell therapies from mesenchymal stem cells, including an approved treatment for graft-versus-host disease.
Develops cell therapies from mesenchymal stem cells, including an approved treatment for graft-versus-host disease.
Until Ryoncil's approval in late 2024 it lived on investor funding and licensing fees; since the 2025 US launch it earns product sales through transplant centers treating children, while its heart-failure and back-pain programmes are paid for from capital raised. The company is Melbourne-based, with an ADR listing in the US.
In one line: A small-cap cell-therapy biotech, like a mini Bluebird Bio.
Moat: narrow (IP / patents). Patented mesenchymal stem cell platform and a rare FDA-approved cell therapy product.
Headquarters: Melbourne, Australia · Founded: 2004 · Employees: 108
Size Mesoblast (MSB.AX) is an Australia Health Care company (Biotechnology) with a market value of $1.49B, the 138th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.76 on 18 Nov 2026.
Performance Over six months the shares fell 17.0%, against -6.9% for the median peer and +1.2% for the Australia market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 555.7% over the last twelve months (peer median +24.8%); the operating margin is -43.2% (peer median -9.6%).
Valuation It trades at 12.8× enterprise value to sales against a peer median of 10.1× (9th most expensive of 18).
Capital Return on invested capital runs 19.2 points below its cost of capital (13.0% WACC).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$176M | A$177M | A$26.6M | A$9.01M | A$11.2M |
| Revenue growth | — | +568% | +195% | -19% | — |
| Gross profit | A$148M | A$149M | A$8.75M | -A$15.0M | -A$30.1M |
| EBITDA | -A$63.5M | -A$63.0M | -A$86.7M | -A$82.6M | -A$102M |
| Net income | -A$86.0M | -A$84.9M | -A$158M | -A$134M | -A$122M |
| Free cash flow | -A$96.5M | -A$100M | -A$88.4M | -A$85.5M | -A$103M |
| Capital expenditure | A$1.28M | A$1.33M | A$1.13M | A$505,054 | A$466,773 |
| Total debt | n/a | A$184M | A$196M | A$178M | A$175M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mesoblast MSB.AX | $1.49B | -17% | +556% | -43% | 12.8× | n/a |
| Vericel VCEL | $2.99B | +66% | +25% | 8% | 9.0× | 46.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MSB.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | 0.0% | -12.7% | 4th highest of 21 |
| 6-month return | -17.0% | -6.9% | 9th lowest of 20 |
| Distance from 52-week high | -46.8% | -44.1% | 9th lowest of 21 |
| Revenue growth (TTM) | +555.7% | +24.8% | 5th highest of 18 |
| Operating margin | -43.2% | -9.6% | 9th lowest of 19 |
| EV / Sales | 12.8× | 10.1× | 9th most expensive of 18 |
| ROIC minus cost of capital | -19.2 pp | -9.5 pp | 5th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |